Pharma News
Intas enters top 20 generics firms through Actavis purchase
Intas Pharmaceuticals (Intas) has completed a deal to acquire Actavis UK and Actavis Ireland (Actavis UK and Ireland) from Teva Pharmaceutical (Teva) for over GBP 600 million.
Baxter expands injectables portfolio with purchase of Claris Injectables
US-based Baxter International Inc (Baxter) has announced its acquisition of India’s Claris Injectables Ltd, which will enhance the company’s position in the global injectables market.
Mabion signs agreement with Mylan for rituximab biosimilar
Global specialty pharmaceuticals firm Mylan has reached an agreement with Mabion, a leading biotechnology company in Poland, for the exclusive right to commercialize their rituximab biosimilar candidate in the European Union (EU).
Eagle moves into biosimilars with Arsia acquisition
Specialty pharmaceuticals company Eagle Pharmaceuticals (Eagle) has signed an agreement to acquire Arsia Therapeutics (Arsia), the biotechnology company behind cutting-edge technology that enables intravenous drugs to be administered by injection.
Top 10 most read GaBI Online articles in 2016
It has once again been a busy year for biosimilars. An important milestone for biosimilars in 2016 was the adoption by the European Medicines Agency (EMA) of new guidance on monitoring biologicals. While the US Food and Drug Administration (FDA) approvals of infliximab and adalimumab biosimilars were also important events in 2016. Other subjects of interest for biosimilars were the differences between biosimilars and reference biologicals, biosimilarity and switching biosimilars. Biosimilars remain the hot topic for GaBI Online during 2016.
Strategic biologicals alliance between Sanofi and JHL Biotech in China
Sanofi and JHL Biotech (JHL) announced on 5 December 2016 that they were forming a strategic biologics alliance in China. The two companies will be collaborating on the development and commercialization of biological therapeutics in China, with potential for further international expansion.
Sun Pharma to acquire Russia’s Biosintez
Sun Pharmaceutical Industries (Sun Pharma) announced on 23 November 2016 its acquisition of Russian pharmaceutical company JSC Biosintez at a cost of US$24 million, demonstrating the company’s commitment to the Russian market.
India’s Cipla to establish biosimilars facility in South Africa
Indian generics maker Cipla has announced a deal to set up South Africa’s first biosimilars manufacturing facility, at an estimated cost of over US$91 million.
Richter and DM Bio make deal for trastuzumab biosimilar
Hungary-based Gedeon Richter (Richter) announced on 19 October 2016 that it had signed a technology transfer and in-licensing agreement with South Korea-based biologicals specialist DM Bio for the development and commercialization of DM Bio’s trastuzumab biosimilar.
China’s CFDA rejects more than 80% of drug applications
Data released by China Food and Drug Administration (CFDA) revealed that between January 2015 and January 2016, 1,184 drug applications submitted to CFDA were rejected or withdrawn due to incomplete or fraudulent clinical data.
